Real-time Estimate
Cboe BZX
02:16:17 2024-06-10 pm EDT
|
5-day change
|
1st Jan Change
|
110.9
USD
|
-2.68%
|
|
-2.63%
|
+40.06%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
2,011
|
3,382
|
2,083
|
2,082
|
3,877
|
5,734
|
-
|
-
|
Enterprise Value (EV)
1 |
1,837
|
3,227
|
2,021
|
2,082
|
3,935
|
5,843
|
5,858
|
5,849
|
P/E ratio
|
147
x
|
-27.9
x
|
-41.5
x
|
-20.9
x
|
-28.6
x
|
-44.4
x
|
-71.6
x
|
-195
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
8.49
x
|
15
x
|
7.08
x
|
7.36
x
|
12.3
x
|
15.8
x
|
12.8
x
|
10.3
x
|
EV / Revenue
|
7.75
x
|
14.3
x
|
6.87
x
|
7.36
x
|
12.5
x
|
16.1
x
|
13.1
x
|
10.5
x
|
EV / EBITDA
|
-41.8
x
|
-34.3
x
|
258
x
|
-37.8
x
|
-56.1
x
|
-68.2
x
|
-130
x
|
468
x
|
EV / FCF
|
-361
x
|
-108
x
|
-87.6
x
|
-32.9
x
|
-50.4
x
|
-122
x
|
-598
x
|
96.7
x
|
FCF Yield
|
-0.28%
|
-0.93%
|
-1.14%
|
-3.04%
|
-1.98%
|
-0.82%
|
-0.17%
|
1.03%
|
Price to Book
|
3.52
x
|
5.1
x
|
3.55
x
|
3.94
x
|
8.46
x
|
11.8
x
|
11.1
x
|
9.5
x
|
Nbr of stocks (in thousands)
|
36,917
|
44,933
|
46,862
|
47,675
|
48,772
|
50,340
|
-
|
-
|
Reference price
2 |
54.47
|
75.26
|
44.44
|
43.68
|
79.49
|
113.9
|
113.9
|
113.9
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/22/22
|
2/22/23
|
2/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
237
|
225
|
294
|
282.9
|
314.7
|
362.7
|
448.7
|
557.7
|
EBITDA
1 |
-43.99
|
-94.17
|
7.825
|
-55.13
|
-70.13
|
-85.63
|
-44.94
|
12.5
|
EBIT
1 |
-50.29
|
-48.21
|
-21.84
|
-86.7
|
-103.8
|
-104.6
|
-64.51
|
-6.118
|
Operating Margin
|
-21.22%
|
-21.43%
|
-7.43%
|
-30.65%
|
-32.98%
|
-28.84%
|
-14.38%
|
-1.1%
|
Earnings before Tax (EBT)
1 |
-50.04
|
-132.3
|
-
|
-
|
-133.7
|
-115
|
-74.52
|
-20.3
|
Net income
1 |
15.42
|
-120.3
|
-49.59
|
-99.2
|
-134.7
|
-127.9
|
-79.8
|
-29.16
|
Net margin
|
6.51%
|
-53.5%
|
-16.87%
|
-35.07%
|
-42.79%
|
-35.26%
|
-17.79%
|
-5.23%
|
EPS
2 |
0.3700
|
-2.700
|
-1.070
|
-2.090
|
-2.780
|
-2.564
|
-1.591
|
-0.5829
|
Free Cash Flow
1 |
-5.093
|
-29.92
|
-23.08
|
-63.35
|
-78.01
|
-47.95
|
-9.8
|
60.5
|
FCF margin
|
-2.15%
|
-13.3%
|
-7.85%
|
-22.4%
|
-24.79%
|
-13.22%
|
-2.18%
|
10.85%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
484.12%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/22/22
|
2/22/23
|
2/21/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
73.24
|
67.68
|
72.68
|
71.27
|
71.23
|
73.9
|
80.4
|
78.05
|
82.36
|
85.62
|
88.9
|
89.71
|
98.63
|
103.3
|
111.4
|
EBITDA
1 |
-2.813
|
-6.028
|
-21.1
|
-7.394
|
-19.24
|
-18.46
|
-12.98
|
-13.33
|
-23.88
|
-23.92
|
-20.55
|
-19.58
|
-20.21
|
-16.03
|
-11.37
|
EBIT
1 |
-10.32
|
-13.64
|
-30.36
|
-15.29
|
-27.42
|
-26.76
|
-22.85
|
-21.78
|
-32.39
|
-32.84
|
-24.45
|
-24.08
|
-23.93
|
-20.63
|
-14.96
|
Operating Margin
|
-14.08%
|
-20.15%
|
-41.77%
|
-21.45%
|
-38.5%
|
-36.22%
|
-28.42%
|
-27.91%
|
-39.33%
|
-38.35%
|
-27.5%
|
-26.85%
|
-24.26%
|
-19.96%
|
-13.43%
|
Earnings before Tax (EBT)
1 |
-22.24
|
5.703
|
-45.64
|
-27.33
|
-31.16
|
-34.22
|
-32.38
|
-30.41
|
-36.72
|
-40.46
|
-27.57
|
-26.39
|
-27.15
|
-23.38
|
-18.78
|
Net income
1 |
-21.87
|
5.377
|
-45.54
|
-27.58
|
-31.46
|
-34.63
|
-32.81
|
-30.44
|
-36.78
|
-40.84
|
-29.44
|
-28.84
|
-28.96
|
-24.34
|
-18.2
|
Net margin
|
-29.86%
|
7.94%
|
-62.65%
|
-38.69%
|
-44.17%
|
-46.86%
|
-40.81%
|
-39.01%
|
-44.65%
|
-47.7%
|
-33.11%
|
-32.15%
|
-29.36%
|
-23.55%
|
-16.35%
|
EPS
2 |
-0.4700
|
0.1100
|
-0.9600
|
-0.5800
|
-0.6600
|
-0.7200
|
-0.6800
|
-0.6300
|
-0.7500
|
-0.8200
|
-0.5888
|
-0.5862
|
-0.5800
|
-0.4960
|
-0.3760
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/22/22
|
5/4/22
|
8/3/22
|
11/2/22
|
2/22/23
|
5/3/23
|
8/2/23
|
11/1/23
|
2/21/24
|
5/1/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
57.9
|
109
|
124
|
115
|
Net Cash position
1 |
174
|
154
|
61.3
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-0.8253
x
|
-1.268
x
|
-2.764
x
|
9.207
x
|
Free Cash Flow
1 |
-5.09
|
-29.9
|
-23.1
|
-63.3
|
-78
|
-48
|
-9.8
|
60.5
|
ROE (net income / shareholders' equity)
|
3.64%
|
-7.62%
|
-6.15%
|
-18.5%
|
-22.1%
|
-23.6%
|
-11.2%
|
-2.08%
|
ROA (Net income/ Total Assets)
|
3.01%
|
-5.6%
|
-3.75%
|
-10.1%
|
-11.3%
|
-11.2%
|
-0.23%
|
4.63%
|
Assets
1 |
512.7
|
2,149
|
1,322
|
982.5
|
1,192
|
1,143
|
34,249
|
-629.6
|
Book Value Per Share
2 |
15.50
|
14.80
|
12.50
|
11.10
|
9.400
|
9.610
|
10.30
|
12.00
|
Cash Flow per Share
|
-0.0100
|
-0.5200
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
4.72
|
6.94
|
47.8
|
30.3
|
20.2
|
19.5
|
21.3
|
23.7
|
Capex / Sales
|
1.99%
|
3.08%
|
16.25%
|
10.7%
|
6.43%
|
5.38%
|
4.75%
|
4.24%
|
Announcement Date
|
2/27/20
|
2/25/21
|
2/22/22
|
2/22/23
|
2/21/24
|
-
|
-
|
-
|
Last Close Price
113.9
USD Average target price
115.8
USD Spread / Average Target +1.69% Consensus |
1st Jan change
|
Capi.
|
---|
| +43.30% | 5.73B | | +16.65% | 133B | | -4.36% | 11.52B | | -4.86% | 8.3B | | -22.44% | 4.69B | | +7.79% | 3.42B | | -17.26% | 2.54B | | -13.36% | 2.03B | | -16.39% | 1.86B | | -31.24% | 1.59B |
Medical Devices & Implants
|